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nsulin-like growth factors (IGFs) are essential for skeletal
muscle development, regeneration, and hypertrophy.
Although autocrine actions of IGF-II are known to initiate
myoblast differentiation, the regulatory elements and up-
stream signaling pathways for myogenic expression of IGF-II
remain elusive. Here, we report the regulation of IGF-II
transcription by mTOR, as well as by amino acid sufﬁciency,
through the IGF-II promoter 3 and a downstream enhancer
during C2C12 myoblast differentiation. Furthermore, we
I
 
present evidence that IGF production, and not IGF signaling,
is the primary target for mTOR’s function in the initiation of
differentiation. Moreover, myogenic signaling by mTOR
is independent of its kinase activity and mediated by the
PI3K–Akt pathway. Our ﬁndings represent the ﬁrst identiﬁ-
cation of a signaling pathway that regulates IGF-II expression
in myogenesis and implicate the mTOR–IGF axis as a
molecular link between nutritional levels and skeletal
muscle development.
 
Introduction
 
The insulin-like growth factors (IGF-I and IGF-II) are
critically involved in skeletal muscle development (Florini
et al., 1991a) as well as adult muscle regeneration and hyper-
trophy (Barton-Davis et al., 1999), which require muscle
satellite cell activation and differentiation (Rosenblatt et al.,
1994). The autocrine actions of IGF-II are essential for
the differentiation of satellite cells in culture (Florini et al.,
1991c). However, the regulation of IGF-II expression in
these cells is poorly understood. The IGF-II gene is complex
in structure and its expression can be regulated at many
levels, including transcription from multiple promoters,
alternative translation initiation, mRNA stability, and genomic
imprinting. IGF-II expression during skeletal muscle differ-
entiation is regulated at the transcriptional level, and the
transcripts are derived from promoter 3 (P3; Kou and
Rotwein, 1993). However, the activity of this promoter was
not increased in myotubes compared with myoblasts, and
further analyses of a 25-kb segment around this promoter
region did not reveal any element responsible for myogenic
regulation of IGF-II transcription (Kou and Rotwein, 1993).
Partly due to the lack of information on the relevant cis-acting
regulatory elements, the upstream pathways that directly
instruct the expression of IGF-II in muscle differentiation
are unexplored.
The cellular target of the bacterial macrolide rapamy-
cin, mTOR, belongs to the phosphatidylinositol kinase
(PI3K)-related family of Ser/Thr kinases and functions as a
master regulator of cell growth and proliferation by regulating
multiple downstream effectors (Jacinto and Hall, 2003). In
cell proliferation, the best-characterized function of mTOR
is the regulation of translation initiation through eIF-4E
binding protein 1 (4EBP1) and S6 kinase 1 (S6K1), and the
PI3K pathway acts in parallel with mTOR to regulate
4EBP1 and S6K1 (Fumagalli and Thomas, 2000; Gingras
et al., 2001). The mTOR pathway is believed to mediate
nutrient signals such as amino acid sufficiency (Fumagalli
and Thomas, 2000; Gingras et al., 2001), as well as directly
receive mitogenic signals through a lipid second messenger
(Fang et al., 2001).
Implicated by the inhibitory effect of rapamycin on the
differentiation of a variety of myoblasts in culture (Coolican
et al., 1997; Cuenda and Cohen, 1999; Conejo et al., 2001;
Erbay and Chen, 2001), mTOR’s essential role in skeletal
myogenesis has been demonstrated by the ability of a rapa-
mycin-resistant mTOR mutant to rescue rapamycin-inhibited
differentiation in C2C12 myoblasts (Erbay and Chen, 2001;
Shu et al., 2002). Remarkably, the kinase activity of mTOR
is not required for initiation of differentiation, and both
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S6K1 and 4EBP1 have therefore been excluded as down-
stream mediators of mTOR’s myogenic signaling (Erbay
and Chen, 2001). The molecular events regulated by mTOR
in myogenesis are currently unknown. In this report, we
provide strong evidence that mTOR governs myoblast dif-
ferentiation by controlling the transcription of IGF-II, po-
tentially through a nutrient-sensing pathway.
 
Results and discussion
 
Myogenic transcription of IGF-II is regulated 
through P3 and a skeletal muscle enhancer (ME) 
in a rapamycin-sensitive manner
 
To facilitate the investigation of IGF-II regulation during
myogenesis, we established C2C12 cell pools stably express-
ing a luciferase reporter for P3 of the IGF-II gene. P3 activ-
ity was found slightly decreased in fully formed myotubes
when compared with myoblasts (unpublished data), this
finding is in agreement with a previous work (Kou and Rot-
wein, 1993). However, a closer examination revealed an
acute activation of P3 3 h after the induction of differentia-
tion by growth factor deprivation, which returned to the
basal level by 6 h (Fig. 1 A). As a control, a CMV promoter
reporter displayed no change in luciferase activity under the
same conditions (unpublished data). Remarkably, this in-
creased activity was completely blocked by rapamycin treat-
ment (Fig. 1 A), whereas the CMV-driven luciferase activity
was not affected (not depicted).
This brief activation of P3 alone is insufficient to account
for the continued increase of IGF-II mRNA levels through-
out differentiation (see Fig. 2 A), which prompted us to con-
sider other potential regulatory elements. A recently identi-
fied skeletal ME shared by 
 
IGF-II
 
 and 
 
H19
 
, a gene closely
linked to the 
 
IGF-II
 
 gene and reciprocally imprinted, ap-
peared as a likely candidate (Kaffer et al., 2001). Indeed, the
luciferase activity in C2C12 cells stably expressing the ME
reporter under the control of H19 promoter increased
steadily during differentiation, reaching 
 
 
 
5-fold by 24 h
and 
 
 
 
40-fold by 48 h when compared with 0 h (Fig. 1 B).
The activity of an enhancerless reporter for H19 promoter
did not change under similar conditions (unpublished data).
Importantly, the ME reporter activity was highly sensitive to
rapamycin (Fig. 1 B). Thus, a rapamycin-sensitive pathway
may play a distinct role in the regulation of IGF-II transcrip-
tion through the sequential activation of P3 and ME.
In addition to the mTOR pathway, the PI3K pathway and
p38 MAPK are also required for skeletal myocyte differentia-
tion (Coolican et al., 1997; Kaliman et al., 1998; Cuenda and
Cohen, 1999). However, both P3 and ME activity during dif-
ferentiation were insensitive to the PI3K inhibitor wortman-
nin and the p38 inhibitor SB202190 (Fig. 1, C and D).
 
mTOR is required for IGF-II mRNA production 
in C2C12 cells
 
Consistent with rapamycin’s effect on P3 and ME of IGF-II,
the drastic increase of IGF-II mRNA levels during differen-
tiation was significantly blocked by rapamycin treatment of
differentiating cells, as shown by the results of RNase pro-
tection assays (RPAs) in Fig. 2 A. This inhibition was not
due to changes in IGF-II mRNA stability because during a
12-h window of actinomycin D treatment to suppress tran-
scription, IGF-II mRNA remained highly stable, regardless
of the presence of rapamycin (Fig. 2 B).
To assess whether the rapamycin effect on IGF-II expres-
sion was directly attributable to mTOR, we examined IGF-
II mRNA in C2C12 cell lines stably expressing various re-
combinant FLAG-tagged mTOR proteins including wild
type, rapamycin resistant (RR; S2035T), and RR and kinase
inactive (RR/KI; S2035T/D2357E; Brown et al., 1995).
Several independent clones for each cell line were examined.
The expression of IGF-II mRNA in both RR and RR/KI
cells, but not in wild-type mTOR cells, was insensitive to ra-
pamycin treatment. Fig. 2 (C–E) shows the RPA results
from two representative clones for each cell line. Thus, rapa-
mycin-resistant mTOR, both kinase active and inactive,
fully rescued IGF-II expression from rapamycin inhibition.
Autophosphorylation assays indicated no detectable mTOR
catalytic activity from the recombinant RR/KI proteins in
Figure 1. IGF-II transcription during C2C12 differ-
entiation is regulated through P3 and a skeletal muscle 
enhancer in a rapamycin-sensitive manner. (A and B) 
C2C12 cells stably expressing the P3 (A) or ME (B) 
reporter were induced to differentiate in the absence 
(black bars) or presence (gray bars) of 100 nM rapa-
mycin. At the indicated times, cells were lysed and 
luciferase assays were performed. Proliferating myo-
blasts, 1 d before differentiation ( 24 h), were also 
examined. Relative luciferase activities are shown, with 
those at 0 h set at 1. (C and D) Cells stably expressing 
P3 (C) or ME reporter (D) were induced to differentiate 
for 3 h in the absence of any inhibitor (C) or in the 
presence of 100 nM rapamycin (Rap), 100 nM wort-
mannin (Wort), or 10  M SB202190 (SB). Relative 
luciferase activities are shown, with those at 0 h (0) set 
at 1. All the data are the mean results of three indepen-
dent experiments; SD are shown as error bars. t tests 
were performed to compare each data with that at 0 h. 
*, P   0.001. 
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the stable cells (Fig. 2 F). As expected, the endogenous S6K1
activity was abolished by rapamycin treatment in wild-type
and RR/KI cells, whereas the RR cells yielded a significant
portion of RR S6K1 activity (Fig. 2 G).
Together, our data suggest that during skeletal myogenesis
mTOR regulates the production of IGF-II mRNA. Moreover,
this myogenic function of mTOR is independent of its kinase
activity, which is consistent with our previous observations (Er-
bay and Chen, 2001). This conclusion contradicts that of Shu
et al. (2002) who reported that a C2C12 cell line stably ex-
pressing a kinase-inactive mTOR did not differentiate in the
presence of rapamycin. It is noted that a different mutation
(D2338A) was used to inactivate the kinase by Shu et al. Al-
though D2357E and D2338A are equally effective in inactivat-
ing mTOR’s catalytic activity (Brown et al., 1995), it cannot
be ruled out that D2338A may affect an additional biochemi-
cal property of mTOR. The possibility of clonal variation may
also be considered. To avoid such a potential problem, multi-
ple stable clones were examined in our studies as described in
the previous paragraph, and transient transfection was previ-
ously used to express mTOR (Erbay and Chen, 2001).
 
Amino acid sufficiency is required for acute activation 
of IGF-II transcription
 
Because the mTOR pathway is known to sense the avail-
ability of amino acids in proliferating cells (Fumagalli and
Thomas, 2000; Gingras et al., 2001), we hypothesized that
mTOR may mediate amino acid signals in the regulation of
IGF-II transcription during myogenesis. Indeed, the acute
activation of P3 normally seen at 3 h was abrogated when
amino acids were depleted from the differentiation medium
(Fig. 3). When normal concentrations of amino acids were
replenished for 3 h, activation of P3 was recovered, and this
Figure 2. mTOR controls IGF-II mRNA production 
in C2C12 cells. Parental C2C12 (A and B) and cells 
stably expressing RR (C), RR/KI (D), or wild-type 
mTOR (E) were induced to differentiate in the 
presence or absence of 100 nM rapamycin (Rap). 
(B) On day 1 of differentiation, the cells were 
treated with 2  g/ml actinomycin D (ActD) in the 
presence or absence of 100 nM rapamycin for 
the indicated durations. (C–E) The experiments 
were performed with two independent clones for 
each mTOR cell line as indicated. Total RNA was 
extracted from the cells and IGF-II mRNA levels 
were detected by RPA analyses. The consistency in 
RNA sample loading was confirmed by visualizing 
rRNAs with ethidium bromide staining (A and B 
only). Recombinant mTOR (F) and endogenous 
S6K1 (G) were immunoprecipitated from cells 
stably expressing various mTOR proteins, followed 
by mTOR autokinase assays and S6 kinase assays, 
respectively. (G) Relative S6K1 activities are shown 
for each cell line comparing without or with rapa-
mycin treatment of the cells (100 nM for 45 min). 
All experiments were repeated at least three times 
with similar results. The data are the mean results 
of three independent experiments; SD are shown 
as error bars.
Figure 3. IGF-II transcription during myogenesis is acutely sensitive 
to amino acid deprivation. C2C12 cells stably expressing the P3 
(top) or ME reporter (bottom) were induced to differentiate for 3 h. In 
some of the cells, amino acids were depleted from the differentiation 
medium ( A.A.) and followed by their resupply ( A.A.) for 3 h in 
the presence of inhibitors when indicated; 100 nM rapamycin (Rap), 
100 nM wortmannin (Wort), and 10  M SB202190 (SB). Relative 
luciferase activities are shown, with those at 0 h of differentiation set 
at 1. The data are the mean results of three independent experiments; 
SD are shown as error bars. t tests were performed to compare each 
data with that at 0 h. *, P   0.001. 
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reactivation was completely blocked by rapamycin, but not
by wortmannin or SB202190 (Fig. 3). Similarly, the induc-
tion of ME activity at 3 h was ablated by amino acid depri-
vation and stimulated upon readdition of amino acids (Fig.
3). Again, the reactivation of ME by amino acids was inhib-
ited by rapamycin and was insensitive to wortmannin and
SB202190. The short duration of amino acid withdrawal
ensured that the effect would be the result of affecting a sig-
naling cascade rather than a general stoppage of protein syn-
thesis. Indeed, the CMV-driven luciferase activity was unaf-
fected by amino acid deprivation under similar conditions
(unpublished data).
Circulating IGF levels in animals have previously been
proposed to provide a critical link between the nutritional
status and animal/organ growth (Pilistine et al., 1984), but
molecular mechanisms underlying nutritional regulation of
IGF levels are unknown. Our results provide the first direct
demonstration of IGF-II transcriptional regulation by cellu-
lar amino acid levels, and implicate a potential role for
mTOR in controlling nutritional regulation of IGF-II ex-
pression in skeletal muscle development.
 
mTOR regulates C2C12 differentiation by controlling 
IGF production
 
The regulation of IGF-II transcription by mTOR led us to
hypothesize that mTOR might exert its myogenic function by
controlling IGF-II secretion that is critical for initiation
of the differentiation program. To probe this possibility,
conditioned medium from normally differentiating “donor”
C2C12 cells were transferred daily to “recipient” C2C12 cells
subjected to rapamycin treatment. The recipient cells pro-
ceeded to terminally differentiate despite the presence of rapa-
mycin, evidenced by the formation of sarcomeric myosin
heavy chain (MHC)–positive myotubes (Fig. 4 A, a). Thus, it
appears that rapamycin’s inhibitory effect on differentiation is
through the elimination of a secreted factor. This factor was
confirmed to be IGF-II by the observation that preincubation
with an anti–IGF-II antibody, but not a control rabbit IgG,
completely eliminated the myogenic potency of the donor
medium (Fig. 4 A, b and c). Moreover, conditioned media
from rapamycin-treated RR-mTOR cells, as well as RR/KI-
mTOR cells, conferred rapamycin resistance to the differenti-
ation of the recipient cells (Fig. 4 A, d and e), further validat-
ing the requirement of mTOR and a kinase-independent
mechanism. The neutralizing IGF-II antibody also abolished
the rapamycin-resistant myogenic effects of the media from
the recombinant mTOR-expressing cells (unpublished data).
Furthermore, exogenous IGF-II (at 300 ng/ml) restored
C2C12 differentiation in the presence of rapamycin as
shown by myotube formation (Fig. 4 B) with a differentia-
tion index indistinguishable from that of control cells (Fig.
4 C). Similar rescuing effects were also observed with 150
Figure 4. mTOR regulates C2C12 and primary myo-
blast differentiation by controlling IGF-II secretion. 
(A) Donor cells (not depicted) were induced to differ-
entiate 24 h earlier than the recipient cells. After every 
24 h, the media from the donor cells were transferred 
to the recipient cells in the continuous presence of 
100 nM rapamycin. The donor cells were either 
parental or stable C2C12 cells, whereas all recipient 
cells were parental cells. The recipient cells, fixed and 
stained for MHC after 72 h of differentiation, are shown. 
The identity of donor cells and the treatments of the 
donor media are indicated under the micrographs. 
(B) C2C12 cells (top) or mouse primary myoblasts 
(bottom) were induced to differentiate normally or in 
the presence of 100 nM rapamycin, 300 ng/ml IGF-II, 
or 100 ng/ml IGF-I. The cells were fixed and stained 
for MHC after 72 h of differentiation. (C) Quantification 
of the results in B by differentiation index, calculated 
as the percentage of nuclei in MHC-positive myocytes 
( 500 total nuclei counted for each sample). The mean 
results of three independent experiments are shown, 
with error bars representing SD. 
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ng/ml IGF-II (unpublished data), a concentration compa-
rable to that reportedly secreted by C2C12 cells (Tollefsen
et al., 1989). Interestingly, 100 ng/ml IGF-I was equally
effective (Fig. 4, B and C). The apparently thinner myo-
tubes in the IGF-rescued culture suggests that mTOR may
play a role in myotube morphology independent of IGF
and the initiation of differentiation. Importantly, the dif-
ferentiation of mouse primary myoblasts was inhibited by
rapamycin, which was also reversed by exogenous IGF-I or
IGF-II (Fig. 4, B and C), suggesting that the molecular
mechanisms delineated in C2C12 cells are most likely ap-
plicable to primary cells. In differentiating C2C12 cells,
IGF-II expresses to a much higher level than IGF-I (Tollef-
sen et al., 1989), and IGF-II antisense oligonucleotides are
sufficient to abolish differentiation (Florini et al., 1991c).
The collective evidence is consistent with the notion that
IGF-II is the primary myogenic factor in these cells,
whereas IGF-I can compensate for the lack of IGF-II; both
IGFs presumably signal through the IGF-I receptor. To-
gether, it is apparent that the primary function of mTOR
in the initiation of skeletal muscle differentiation is con-
trolling IGF-II production and not mediating IGF down-
stream signaling.
 
PI3K–Akt pathway is a major mediator of mTOR’s 
myogenic function
 
The PI3K–Akt pathway has been shown to be critical for
IGF’s myogenic signaling (Coolican et al., 1997; Kaliman et
al., 1998). We found that expression of a constitutively ac-
tive (c.a.) Akt reversed the inhibition of C2C12 differentia-
tion by the PI3K inhibitor LY294002 (Fig. 5 A), suggesting
that Akt is the main effector for PI3K signaling in myogene-
sis. Remarkably, c.a.Akt also rescued differentiation from ra-
pamycin inhibition (Fig. 5 A). The results of RPA analysis
indicated that IGF-II mRNA levels were significantly inhib-
ited by rapamycin in c.a.Akt-expressing cells (Fig. 5 C),
which excluded the possibility of enhanced IGF-II produc-
tion independent of mTOR in c.a.Akt cells. These results
imply that the PI3K–Akt pathway is sufficient to mediate
IGF’s myogenic signaling, and they further confirm that reg-
ulation of IGF production is a primary function for mTOR
in myogenesis. It is interesting to note the contrast between
the relationship of these two pathways in myogenesis and
mitogenesis. In cell proliferation, the mTOR pathway and
the PI3K pathway cooperate in a parallel manner to trans-
duce growth factor signals and regulate the same down-
stream targets such as S6K1 (Fumagalli and Thomas, 2000);
whereas in myogenesis, they regulate two sequential pro-
cesses: production of IGF and subsequent IGF signaling, re-
spectively (Fig. 5 D).
In conclusion, we have shown that the autocrine IGF-II
transcription required for skeletal myocyte differentiation is
regulated by mTOR and the availability of amino acids. Al-
though the expression of various myogenic markers, includ-
ing myogenin, p21
 
CIP
 
, and MHC, is also blocked by rapa-
mycin (Cuenda and Cohen, 1999), they are regulated by IGF
signaling (Florini et al., 1991b), and are therefore unlikely to
be directly controlled by mTOR. To the best of our knowl-
edge, this is the first identification of an upstream signaling
pathway in the regulation of IGF production in myogenesis.
Importantly, our findings also suggest a potential role for the
mTOR–IGF axis as a molecular bridge between nutritional
status and skeletal muscle development.
 
Materials and methods
 
Antibodies and other reagents
 
M2 anti-FLAG and HA.11 anti-HA were obtained from Sigma-Aldrich, anti–
IGF-II was obtained from R&D Systems, anti-S6K1 was obtained from Up-
state Biotechnology, and MF20 antisarcomeric MHC was obtained from the
Developmental Studies Hybridoma Bank at the University of Iowa. IGF-I,
Figure 5. Akt is a major mediator of mTOR’s myogenic function. 
C2C12 cells were transfected with wild-type (wt) or constitutively 
active (c.a.) Akt and differentiated in the presence of 100 nM rapa-
mycin (Rap) or 10 mM LY294002 (LY). (A) The cells were fixed and 
stained for MHC after 72 h. (B) Recombinant protein expression was 
confirmed by Western blot analysis using an anti-HA antibody. 
(C) IGF-II mRNA levels were analyzed by RPA in c.a.Akt-expressing 
cells and untransfected C2C12 cells (control). (D) A proposed model 
for mTOR’s myogenic signaling. See Results and discussion for details. 
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IGF-II, gelatin, actinomycin D, and LY294002 were obtained from Sigma-
Aldrich. Rapamycin, wortmannin, and SB202190 were acquired from Cal-
biochem. All other cell culture reagents were obtained from Invitrogen.
 
Plasmids
 
The following plasmids were gifts from various laboratories: pCEFL-HA-
Akt (wild type) and pCMV6-myristoylated-HA-Akt (c.a.) were gifts from N.
Ahmed and J. Blenis (Harvard Medical School, Boston, MA), mouse IGF-II
cDNA was a gift from P. Rotwein (Oregon Health and Science University,
Portland, OR), P3-luc reporter and basic-luc (promoterless) were gifts from
A. Murrell (The Babraham Institute, Cambridge, UK; Murrell et al., 2001),
and H19-luc was a gift from K. Pfeifer (National Institute of Child Health
and Human Development, Bethesda, MD; Pfeifer et al., 1996). CMV-luc
was as previously reported (Kim and Chen, 2000). To assemble the skeletal
ME reporter H19-luc-ME, the SpeI–EagI enhancer fragment (
 
 
 
23 kb to
 
 
 
27 kb) was inserted into a SpeI–EagI linker present in the XhoI site 3
 
 
 
 of
the luciferase in H19-luc.
 
Cell culture and immunofluorescence microscopy
 
C2C12 myoblasts were maintained and differentiated as described previ-
ously (Erbay and Chen, 2001). Primary skeletal myoblasts were isolated
from 2-wk-old mice, grown, and differentiated as previously reported
(Rando and Blau, 1994). Transfections were performed using FUGENE-6
(Roche), and stable clones or pools were selected in 1 mg/ml G418. For
amino acid deprivation and readdition, the cells were cultured in Dul-
becco’s PBS with 4.5 g/liter glucose and 2% dialyzed serum for 3 h and
switched to normal differentiation medium for 3 h. For immunocytochem-
istry, cells were fixed in 3.7% formaldehyde and stained with MHC anti-
body and FITC–anti–mouse IgG. Microscopy was performed on a micro-
scope (model DMIL; Leica) with CPLAN 10
 
 
 
/0.22 NA lenses. The images
were captured using a monochrome charged-couple device camera
(model SPOT RT; Diagnostic Instruments), and processed as 8-bit RGB im-
ages using Adobe Photoshop 7.0.
 
RPA
 
Total RNA from C2C12 cells (in 60-mm plates) was isolated using the
RNeasy mini kit (QIAGEN), and 4 
 
 
 
g of each RNA was applied to RPA us-
ing the RPA III kit (Ambion). Radioactive probes (used at 10
 
6
 
 cpm/ml) were
generated from linearized IGF-II cDNA construct by in vitro transcription
using the MAXIscript kit (Ambion). The samples were run on 5% denatur-
ing polyacrylamide gels and analyzed on a phosphorimager (model Cy-
clone; Packard Instrument Co.). To confirm loading consistency, 1-
 
 
 
g
RNA samples were run on 0.8% agarose-formaldehyde gels, followed by
ethidium bromide staining.
 
Reporter assays
 
C2C12 cells stably expressing CMV-luc, P3-luc, basic-luc, H19-luc, or H19-
luc-ME were grown to 100% confluence and induced to differentiate in 2%
horse serum. Various drug treatments were performed as described in the
figure legends. The cells were lysed at the indicated times, and luciferase as-
says were performed using the Luciferase Assay Systems kit (Promega).
 
Kinase assays
 
mTOR autokinase assays and S6K1 kinase assays were performed as de-
scribed previously (Erbay and Chen, 2001).
 
Statistical analysis
 
t
 
 tests were performed for all data comparisons. Unless specifically indi-
cated in figure legends, significant difference was defined by P 
 
  
 
0.05.
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